Lilly Seeks To Stay Whistleblower Suit Over Zyprexa
Eli Lilly & Co. is seeking to stay a whistleblower suit over charges it marketed its blockbuster anti-psychotic drug Zyprexa for off-label uses, arguing the case should be joined with a...To view the full article, register now.
Already a subscriber? Click here to view full article